



Final Appraisal Recommendation

Sildenafil citrate (Revatio[®]▼) solution

Limited submission by:
Pfizer Ltd

Advice No: 1910 – December 2010

Recommendation of AWMSG

Sildenafil citrate (Revatio[®]▼) solution for injection is recommended within its current licensed indication as an option for use within NHS Wales for the treatment of patients with pulmonary arterial hypertension (PAH) who are currently prescribed oral sildenafil citrate and who are temporarily unable to take oral medicine, but are otherwise clinically and haemodynamically stable.

AWMSG recommends that its use be restricted to a physician experienced in the treatment of PAH.

Sildenafil citrate (Revatio[®]▼) solution for injection is not suitable for shared care within NHS Wales for the above indication.

Additional notes:

The current vial size (40mg in 50ml) may lead to medication administration error and users should be aware of this concern.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary recommendation (PAR) and the applicant company's response to this, clinical expert opinion, lay perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be used without the whole of the advice being quoted in full and should be cited as: